Latest Conference Articles

September 28th 2019, 8:12pm

ESMO Congress: GU Cancers

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.

September 28th 2019, 6:45pm

ESMO Congress: Gynecologic Cancers

Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.

September 28th 2019, 6:40pm

ESMO Congress

The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.

September 28th 2019, 6:39pm

ESMO Congress: Gynecologic Cancers

Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.

September 28th 2019, 6:35pm

ESMO Congress: Lung Cancer

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

September 28th 2019, 6:32pm

ESMO Congress: Gynecologic Cancers

The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.

September 28th 2019, 6:26pm

ESMO Congress: GU Cancers

Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.

September 28th 2019, 5:29pm

ESMO Congress: Gynecologic Cancers

The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.

September 28th 2019, 2:46am

ESMO Congress: Lung Cancer

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.

September 28th 2019, 2:44am

ESMO Congress: GI Cancers

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.

September 28th 2019, 1:23am

ESMO Congress: GI Cancers

Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.

September 27th 2019, 11:58pm

ESMO Congress

Atezolizumab (Tecentriq) monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment of certain patients with wild-type non–small cell lung cancer.

September 27th 2019, 11:44pm

ESMO Congress

More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.

September 27th 2019, 11:01pm

ESMO Congress: GU Cancers

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

September 20th 2019, 11:50pm

International Myeloma Society Annual Meeting

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

September 20th 2019, 11:41pm

International Myeloma Society Annual Meeting

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

September 16th 2019, 11:37pm

International Myeloma Society Annual Meeting

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

September 16th 2019, 9:13pm

International Myeloma Society Annual Meeting

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

September 16th 2019, 9:12pm

International Myeloma Society Annual Meeting

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

September 16th 2019, 8:59pm

International Myeloma Society Annual Meeting

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.